189 related articles for article (PubMed ID: 37850581)
1. Update on Gadolinium Based Contrast Agent Safety, From the
Starekova J; Pirasteh A; Reeder SB
AJR Am J Roentgenol; 2023 Oct; ():. PubMed ID: 37850581
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
Bäuerle T; Saake M; Uder M
Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
[TBL] [Abstract][Full Text] [Related]
4. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
Mathur M; Jones JR; Weinreb JC
Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
[TBL] [Abstract][Full Text] [Related]
6. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
[TBL] [Abstract][Full Text] [Related]
8. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.
Schieda N; Maralani PJ; Hurrell C; Tsampalieros AK; Hiremath S
Can Assoc Radiol J; 2019 Aug; 70(3):226-232. PubMed ID: 31255393
[TBL] [Abstract][Full Text] [Related]
9. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.
Costelloe CM; Amini B; Madewell JE
Semin Ultrasound CT MR; 2020 Apr; 41(2):170-182. PubMed ID: 32446430
[TBL] [Abstract][Full Text] [Related]
10. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.
Lunyera J; Mohottige D; Alexopoulos AS; Campbell H; Cameron CB; Sagalla N; Amrhein TJ; Crowley MJ; Dietch JR; Gordon AM; Kosinski AS; Cantrell S; Williams JW; Gierisch JM; Ear B; Goldstein KM
Ann Intern Med; 2020 Jul; 173(2):110-119. PubMed ID: 32568573
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium tissue deposition in brain and bone.
Murata N; Murata K; Gonzalez-Cuyar LF; Maravilla KR
Magn Reson Imaging; 2016 Dec; 34(10):1359-1365. PubMed ID: 27720805
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis.
MacLeod CA; Gauthier I; Davenport MS; McGrath TA; Khan F; Dos Santos MP; McInnes MDF; Schieda N
J Vasc Interv Radiol; 2023 Apr; 34(4):568-577.e10. PubMed ID: 36464013
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Patient with Reported Gadolinium-Associated Illness.
Lyapustina T; Goldfine C; Rhyee S; Babu KM; Griswold MK
J Med Toxicol; 2019 Jan; 15(1):36-44. PubMed ID: 30499040
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
[TBL] [Abstract][Full Text] [Related]
17. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.
Zou Z; Ma L
Indian J Dermatol; 2011 Jan; 56(1):65-73. PubMed ID: 21572796
[TBL] [Abstract][Full Text] [Related]
19. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis.
Schieda N; van der Pol CB; Walker D; Tsampalieros AK; Maralani PJ; Woo S; Davenport MS
Radiology; 2020 Dec; 297(3):565-572. PubMed ID: 32452732
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
